Drug Trial Radar · NCT05281263
Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults
Last checked: Nov 19, 2026Latest source record: Dec 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jul 20, 2022
Primary completion
Dec 5, 2022
Study completion May 3, 2023
Sponsor
- Lead sponsor
- Blue Lake Biotechnology Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1 trial is an open-label trial to evaluate the safety, tolerability and immunogenicity of a single dose (10\^7.5 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered as a single dose in 15 healthy young adults ages 18-59 years, and 15 older adults ages 60-75 years.
Conditions
- Respiratory Syncytial Virus Infections
Interventions
CPI-RSV-F Vaccine (BLB-201)Biological
see arm/group description
Primary outcomes
What the sponsor says the trial is designed to measure.
- Solicited Adverse EventsTime frame: Day 1-8
- Unsolicited Adverse EventsTime frame: Day 1-29
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Coastal Carolina Research Center
North Charleston, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.